Shots:

• The P-III TiNivo-2 study involves assessing Fotivda (1.34 mg/qd for 21days followed by 7days off treatment) + Opdivo (480 mg- q4w) in ~326 patients in a ratio (1:1) with advanced r/r metastatic RCC following prior immunotherapy exposure
• The study plans to enroll patients across the US- EU- and Latin America. The 1EP of the study is PFS while the 2EPs include OS- ORR- DoR & safety
• Additionally- BMS will provide Opdivo clinical drug supply for the study and AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution

 ­ Ref: Businesswire | Image: BMS